Last checked at 7 Jun 2021 07:00
7 June 2021
Diaceutics PLC
("Diaceutics" or "the Group")
Notice of Capital Markets Day
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that it will be hosting a virtual Capital Markets Day ("CMD") for investors and equity analysts on Wednesday 16th June 2021, starting at 13:00pm BST.
The event will be hosted by Group CEO, Peter Keeling, and will include a series of presentations, a demonstration of the DXRX SaaS platform, views from an industry expert panel including:
· Pharmaceutical Partner: a senior executive within one of the world's top five pharmaceutical companies
· Laboratory Partner: Professor Giancarlo Pruneri, Head of Pathology Fondazione IRCCS Istituto Nazionale Tumori, Milan
· Key Opinion Leader: Dr Avi Kulkarni, SVP and R&D leader at Nasdaq listed technology firm Cognizant
In addition, there will be a strategic update from the Company, along with a live Q&A.
A video replay of the presentation will be available via the Group's website post-event.
If you are interested in attending or have any questions relating to the Diaceutics Capital Markets Day please contact diaceutics@almapr.co.uk
Enquiries:
Diaceutics PLC Peter Keeling, Chief Executive Officer Philip White, Chief Financial Officer
| www.diaceutics.com via Alma PR |
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison Stewart Wallace Nick Adams
| +44 (0)20 7710 7600 |
Alma PR Caroline Forde Robyn Fisher Kieran Breheny | Tel: +44 (0)20 3405 0205 diaceutics@almapr.co.uk |
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.